Comparative pharmacogenomics of antiretroviral and cytotoxic treatments

Time to Undetectable Viral Load after Highly Active Antiretroviral Therapy Initiation among HIV-Infected Pregnant Women

“…Additionally, we used a treatment propensity score to reduce at SUNY Health Science Center at Brooklyn -Medical Research Library on March 17, 2015 http://cid.oxfordjournals.org/ Downloaded from bias in the comparison of a treatment group to a nonrandomized control group [6]. We could not account for additional factors potentially influencing response to HAART, such as adherence, biological differences in drug activity arising from variations in body weight and pharmacokinetics between groups, HIV subtypes, and other genetic factors [14,33,34]. A disadvantage of cohort data is their limited contemporary relevance when therapeutic practices have changed over time.…”

HIV and Lung Cancer

“…These enzymes are used in metabolic pathways with ifosfamide, docetaxel, paclitaxel, irinotecan, vinca alkaloids, and etoposide. (Rowinsky & Donehower, 1997, Stebbing & Bower, 2006 Severe myelosuppression with atazanavir (Richman et al, 1987, Tan & Ratner, 1997 and peripheral neuropathy with didanosine, stavudine, and zalcitabine occur. (Rowinsky & Donehower, 1997) Thus, their combined use with platinum or paclitaxel leads to increased toxicities.…”